{"ticker": {"uuid": "40fb5f7b-26b8-4684-8f2e-84da176db694", "symbol": "FBIO", "name": "Fortress Biotech Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Fortress Biotech Stock - Saturday deep dive on the business model", "summary": "This article provides a deep dive into Fortress Biotech's business model, highlighting its \"hub-and-spoke\" structure through majority or minority-owned subsidiaries. The company acquires and develops biopharmaceutical product candidates in various therapeutic areas like oncology,", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/fortress-biotech-stock-saturday-deep-dive-on-the-business-model/69592719", "source_name": "AD HOC NEWS", "published_at": "2026-06-20T18:43:29", "published_display": "20 Jun 2026 18:43", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fortress Biotech Inc (FBIO) Risk Assessment: Volatility, Financial Risk & Investment Risk", "summary": "", "url": "https://news.google.com/rss/articles/CBMid0FVX3lxTE1wVzV5Rk9sOGNYenZ4Mmk1OVJwMXZaUFBXYUhMNGptWmZqMW1LVmR3cXZOR25yeDV2ZnJwVm0xMFVKRC10bnIyeDl4WTctZGs1SlI1QTh3Rm9jY2VKZXItaWlKa3Vzd25ubkdLSTJGc1dxVnluR01B?oc=5", "source_name": "TradingKey", "published_at": "2026-06-18T10:50:00+00:00", "published_display": "18 Jun 2026 10:50", "sentiment": "negative", "sentiment_pct": 5, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fortress Biotech Inc (FBIO) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Fortress Biotech Inc (FBIO), highlighting its current price momentum score of 8.51 and its position between resistance and support levels. It details various technical indicators like MACD, RSI, and moving averages, offering buy/sell ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-fbio/technical", "source_name": "TradingKey", "published_at": "2026-06-18T11:10:40", "published_display": "18 Jun 2026 11:10", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fortress Biotech Inc (FBIO) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a valuation analysis of Fortress Biotech Inc (FBIO) by TradingKey. It details the company's current valuation score of 9.14, ranking it 48th out of 157 in the Pharmaceuticals industry, and highlights its P/E ratio of 0.80. The article also notes that relevan", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-fbio/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-18T11:10:40", "published_display": "18 Jun 2026 11:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fortress Biotech Inc stock (US32015L1035): Nasdaq-listed biotech moves in low-volume trade ahead of", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxPU0Y4b3M4OEpEOE1VZUJMazVCM0NVT1hTTm41UWRFZFQ3b2E2TFBQMjRHS01SX2R3SUlTZTh5SW9WeHJDd0pHMFlvc1JSc09zbFdaaHBNWmlaTjMzY1F2V0xBVlVaYVQ5eHp1ZVg1YWRTeUVMMnFWd3c4aVhkcEhFU3hhZFp1QUJSRkc3N3ltdXRpSndNNEt0T0NSemFCb1B5TGt3cnd5WlZmeWoxU3M2VGxibzdKcVJMU2ZyUHFxS3VFSEZEZWJFRQ?oc=5", "source_name": "AD HOC NEWS", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fortress Biotech: Is It Time To Pay The Deferred Preferred Stock Dividends? (FBIO)", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxNelREUjIyQ2pLUExaUmZWMVVTNXliRzBxbHpBODdfZWFsbm9USF9FenlxMGpOazhkT094dTRMd1Z5NXZjejlKT0E5bklHQkhsWHNxTzY5bzVZSzN0Mk5uY0Y4emJLajcwY1RyY3phdmhxVFhxVXdOdDFfSFpZWmVTd3lwdnV3c1B3eVlETVNkakJCNEhiVlV5M3c2MGJiOWNzVzdEN1NMcTV0a24wVl80?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-05-29T07:00:00+00:00", "published_display": "29 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fortress Biotech to Participate in A.G.P.\u2019s Annual Virtual Healthcare Conference", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/fortress-biotech-participate-g-p-123000153.html", "source_name": "GlobeNewswire", "published_at": "2026-05-18T12:30:00+00:00", "published_display": "18 May 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Fortress Biotech: Q1 Earnings Snapshot", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/fortress-biotech-q1-earnings-snapshot-205038341.html", "source_name": "Associated Press", "published_at": "2026-05-14T20:50:38+00:00", "published_display": "14 May 2026 20:50", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fortress Biotech stock (US32015L1035): Q1 earnings miss on revenue, but EMROSI shows momentum", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxOUDJvVzJSMkNKaWUzY0RLRTBZSzNfeTVjTnVjRndjVWJwaXY5OW9TTDkwWGJIUXpINGJjUmVTQjNudUNrNFlsLWZFWnU0RUl3Vi0tQmxtWWdxU1BCSldVbDNuSWYwYnpYMmw3QkIzYVhzR0I2c3JfYld5NlNhSENjSnF5RF9xakhXZ2xUbGxUUC04dDlTVkdaa0htRy1ESS12eEtTd1E5UnByV0s1YjFZbHhhclFDOHJybHcxN09EMDllanIw?oc=5", "source_name": "AD HOC NEWS", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Fortress Biotech Reports First Quarter 2026 Financial Results and Recent Corporate Highlights", "summary": "Fortress Biotech (FBIO) reported strong first-quarter 2026 financial results, with consolidated net income attributable to common stockholders reaching $108.4 million or $3.44 per share (basic). Key drivers included the FDA approval of ZYCUBO\u00ae for Menkes disease and the subsequen", "url": "https://www.globenewswire.com/news-release/2026/05/14/3295389/0/en/fortress-biotech-reports-first-quarter-2026-financial-results-and-recent-corporate-highlights.html", "source_name": "GlobeNewswire", "published_at": "2026-05-13T12:09:19", "published_display": "13 May 2026 12:09", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Fortress Biotech to Participate in the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/fortress-biotech-participate-h-c-123000795.html", "source_name": "GlobeNewswire", "published_at": "2026-05-04T12:30:00+00:00", "published_display": "04 May 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fortress Biotech to Receive $205M as Cyprium Agrees Sale of Rare Pediatric Disease Priority Review Voucher", "summary": "Fortress Biotech (FBIO) has announced that Cyprium Therapeutics, a company in which Fortress owns a substantial equity stake, has entered into an agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for $205 million. This sale is expected to generate signifi", "url": "https://www.msn.com/zh-hk/health/other/fortress-biotech-to-receive-205m-as-cyprium-agrees-sale-of-rare-pediatric-disease-priority-review-voucher/ar-AA1WUaUu?apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1&bundles=feat-es2020-t", "source_name": "MSN", "published_at": "2026-04-28T23:39:35", "published_display": "28 Apr 2026 23:39", "sentiment": "positive", "sentiment_pct": 86, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Fortress Biotech Reports 2025 Financial Results and Recent Corporate Highlights", "summary": "Fortress Biotech (Nasdaq: FBIO) announced its financial results for the full-year ended December 31, 2025, detailing significant corporate achievements including asset monetizations, regulatory approvals, and advancements in clinical programs. Key highlights include the FDA appro", "url": "https://www.globenewswire.com/news-release/2026/03/31/3266013/28889/en/fortress-biotech-reports-2025-financial-results-and-recent-corporate-highlights.html", "source_name": "GlobeNewswire", "published_at": "2026-04-08T12:39:53", "published_display": "08 Apr 2026 12:39", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fortress Biotech (FBIO) CFO adds 2,967 ESPP shares in exempt grant", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxNM3pUNjNlcGtvYzFBMng4LWJjc0Fpb3NWR1BGY3l0VXhtWVBnNHBvamNuSUJ2QmFqOTBGOExEa084VDVRUWdZeXRZVTQxazJzRzlaNFVtY2ZKY0JPZ3NmMUd5TXNSQTlTNEZKM01UZlg0TVZPblFCZXpyUzljOWQ1NU5ReExVMDRuY09wQWREQkNLYlN5S1k4WUd1dUE2MmF4Z3JESk5uOXdJZTEwLTZ2N2JNaG4?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-01T07:00:00+00:00", "published_display": "01 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fortress Biotech: Q4 Earnings Snapshot", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/fortress-biotech-q4-earnings-snapshot-214658970.html", "source_name": "Associated Press", "published_at": "2026-03-31T21:46:58+00:00", "published_display": "31 Mar 2026 21:46", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rare-disease voucher sale brings Fortress more than $100M", "summary": "Fortress Biotech's subsidiary, Cyprium Therapeutics, has completed the sale of its Rare Pediatric Disease Priority Review Voucher for $205 million. Fortress Biotech anticipates receiving over $100 million from this transaction, which will enhance its financial flexibility for bus", "url": "https://www.stocktitan.net/news/FBIO/fortress-biotech-s-subsidiary-cyprium-therapeutics-closes-sale-of-wlq4ml23znh3.html", "source_name": "Stock Titan", "published_at": "2026-03-30T20:10:15", "published_display": "30 Mar 2026 20:10", "sentiment": "positive", "sentiment_pct": 89, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fortress Biotech\u2019s Subsidiary Cyprium Therapeutics Closes Sale of Rare Pediatric Disease Priority Review Voucher for $205 Million", "summary": "Fortress Biotech's subsidiary, Cyprium Therapeutics, has completed the sale of its Rare Pediatric Disease Priority Review Voucher (PRV) for $205 million. Fortress expects to receive over $100 million from the transaction, enhancing its financial flexibility. The PRV was issued fo", "url": "https://www.manilatimes.net/2026/03/31/tmt-newswire/globenewswire/fortress-biotechs-subsidiary-cyprium-therapeutics-closes-sale-of-rare-pediatric-disease-priority-review-voucher-for-205-million/2310900", "source_name": "The Manila Times", "published_at": "2026-03-30T20:10:15", "published_display": "30 Mar 2026 20:10", "sentiment": "positive", "sentiment_pct": 74, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fortress Biotech\u2019s Subsidiary Cyprium Therapeutics Closes", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwJBVV95cUxOS2lSSVZtcWFYMlo0YkZleDV4eWNVOHlJWGdlZlJTeDVyZUZ0ZlpTYXN3Yi00UVZDMjlkaHJIMFVjbXAxMVdCMWd6S3N3YktqTnl3ekhCeGdfNkZnbVRDOGxEUENuZHJZWDBCYWFWUVEySmQtZHhUcWdGaF85dmdJeHhlWTY1ZHhEaEQzd2gwQVplTFhzVENuam0yU2pYVkRFNEQ2VWlNaGd5eHhnWG9UZzhCQy1mV1NITG5yN0RGajJwLWozWGdaSmFZbzR4R09CMTVPVXAyRjFqbVo3WG5MVF9ybFFaaVc2a0M2UDQzTllwQU9SdXl4c3NkeUVLb3dMc281R0ZtZ09PSkRUNkdJN21qRFVWME91T1Bjb3JNWlV2TTQ2SjNn?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-03-30T07:00:00+00:00", "published_display": "30 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxNZXlTZHFHZVNxMktqZ0hVNURmdE1hUFpZZnlfdEVhMnVla2EyTWN6b2YwNkVhNllxUy1Bczl2a0ZUNk04Q3oyTEZSajdpMnFDVXJfRTlfLUdHQ05uS3FQZkhNWkJ0MDFENDJvRXR0ZGV1RDlYVmdWem96V29NeTg4YWRZWGNoMzM1emRoSExJbXdwZnJIWHpsYjVnT0FQVHZtUW5iVg?oc=5", "source_name": "Market source", "published_at": "2026-03-30T07:00:00+00:00", "published_display": "30 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "This Small-Cap Biotech Stock Is Soaring 29% on Excitement Over Its Prostate Cancer Drug", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxPSG1pQzVIRmhqTkhiWXozT29mTWM0UERfakxmOTZzdm5TZ24wZTVqLUpSWlFyWGVmYnlicGE3ZVYxOVotWU5naGM5aUZVakItUGJLTk1ZVE1mclRHd1N3N0FIWkV2TzFrT2lMNFRjcHhnVVBzTk5vNUFkLTgwNExtRWJYN1hVZzRkVjRlTktkNk1jcnpfQklCamN3NA?oc=5", "source_name": "Barron's", "published_at": "2026-02-24T08:00:00+00:00", "published_display": "24 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FBIO Shares Rally After Unit Sells Priority Review Voucher For $205 Million: Retail Now Pins Hopes On Gene Therapy", "summary": "Fortress Biotech's shares rallied by 10% after its majority-owned unit, Cyprium Therapeutics, sold a Rare Pediatric Disease Priority Review Voucher for $205 million to Sentynl Therapeutics. The voucher was issued following the FDA approval of ZYCUBO for Menkes disease, and 20% of", "url": "https://stocktwits.com/news-articles/markets/equity/fbio-shares-rally-after-unit-sells-priority-review-voucher/cZRtxGmR4yo/amp", "source_name": "Stocktwits", "published_at": "2026-02-23T17:08:57", "published_display": "23 Feb 2026 17:08", "sentiment": "positive", "sentiment_pct": 74, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fortress Biotech Inc. Shares Soar After Promising New Developments", "summary": "Fortress Biotech Inc. (FBIO) shares have risen by 9.97% due to positive market reactions to regulatory approvals, strategic partnerships, and strong revenue growth. The company reported $57.7M in revenue and an impressive 71.6% gross margin, with analysts remaining bullish on its", "url": "https://www.timothysykes.com/news/fortress-biotech-inc-fbio-news-2026_02_23-2/", "source_name": "Timothy Sykes", "published_at": "2026-02-23T16:45:48", "published_display": "23 Feb 2026 16:45", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UPDATE: Fortress Biotech\u2019s Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million", "summary": "Fortress Biotech's majority-owned subsidiary, Cyprium Therapeutics, has announced an agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for $205 million. This PRV was issued following the FDA approval of ZYCUBO for Menkes disease, with Sentynl Therapeutics", "url": "https://www.globenewswire.com/news-release/2026/02/23/3242714/28889/en/UPDATE-Fortress-Biotech-s-Subsidiary-Cyprium-Therapeutics-Enters-into-Agreement-to-Sell-Rare-Pediatric-Disease-Priority-Review-Voucher-for-205-Million.html", "source_name": "GlobeNewswire", "published_at": "2026-02-23T14:24:38", "published_display": "23 Feb 2026 14:24", "sentiment": "positive", "sentiment_pct": 72, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fortress Biotech, Inc. and Cyprium Therapeutics Enter Asset Purchase Agreement for $205 Million Rare Pediatric Disease Priority Review Voucher", "summary": "Fortress Biotech, Inc. and its subsidiary Cyprium Therapeutics have agreed to sell a Rare Pediatric Disease Priority Review Voucher for $205 million. This voucher was obtained after the FDA approved ZYCUBO for Menkes disease, with Sentynl Therapeutics handling its commercializati", "url": "https://www.quiverquant.com/news/Fortress+Biotech%2C+Inc.+and+Cyprium+Therapeutics+Enter+Asset+Purchase+Agreement+for+%24205+Million+Rare+Pediatric+Disease+Priority+Review+Voucher", "source_name": "Quiver Quantitative", "published_at": "2026-02-23T14:08:57", "published_display": "23 Feb 2026 14:08", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fortress Biotech's Cyprium To Sell $205 Million Priority Review Voucher; Shares Rise", "summary": "Fortress Biotech's majority-owned subsidiary, Cyprium Therapeutics, has agreed to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for $205 million. This follows the FDA approval of ZUCUBO for Menkes disease. Fortress Biotech (FBIO) shares rose 20% on the news, refle", "url": "https://www.rttnews.com/3624075/fortress-biotech-s-cyprium-to-sell-205-million-priority-review-voucher-shares-rise.aspx", "source_name": "RTTNews", "published_at": "2026-02-23T10:12:00", "published_display": "23 Feb 2026 10:12", "sentiment": "positive", "sentiment_pct": 74, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fortress Biotech (NASDAQ:FBIO) Shares Cross Above 200-Day Moving Average - Here's What Happened", "summary": "Fortress Biotech (NASDAQ:FBIO) shares have surpassed their 200-day moving average, trading as high as $3.54 and closing at $3.45 on Wednesday. The company holds a \"Moderate Buy\" consensus rating from analysts with a target price of $16.50. Wall Street Zen and Zacks recently upgra", "url": "https://www.marketbeat.com/instant-alerts/fortress-biotech-nasdaqfbio-shares-cross-above-200-day-moving-average-heres-what-happened-2026-02-19/", "source_name": "MarketBeat", "published_at": "2026-02-19T09:27:19", "published_display": "19 Feb 2026 09:27", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fortress Biotech: The PRV Catalyst That Could Reprice This Microcap", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxPQi14VVlUSUNmM1JubXFxZ19jVkNBOWpkU01zWEt6Mm4zTnZwSXRhZ3pMVFhFSmhCQUp4ZHZxUjNsUnZ0cUR4UEhRZkI3aERudlFhdTZFcUFxOVJGb044bElybWk1a2VPbnpqRFdGSzBRRHphdlVQYjVmZVNKd2tERUxFcENqZ252YWYtSnhHRXFwcGxkYnVGekZJdW91QUMwUDVQcEVqd2JRNm8?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-02-19T08:00:00+00:00", "published_display": "19 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Behavioral Patterns of FBIOP and Institutional Flows", "summary": "This article analyzes Fortress Biotech Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock (NASDAQ: FBIOP), highlighting weak near and mid-term sentiment but a strong long-term outlook. It presents three AI-generated trading strategies\u2014Position, Momentum Breakout", "url": "https://news.stocktradersdaily.com/news_release/38/Behavioral_Patterns_of_FBIOP_and_Institutional_Flows_021326022802_1771010882.html", "source_name": "Stock Traders Daily", "published_at": "2026-02-13T14:28:00", "published_display": "13 Feb 2026 14:28", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fortress Biotech (NASDAQ:FBIO) Shares Cross Above 200-Day Moving Average - What's Next?", "summary": "Fortress Biotech (NASDAQ:FBIO) shares have risen above their 200-day moving average, reaching $3.74 on high volume, which is considered a bullish technical signal. The company's fundamentals are mixed, with a market capitalization of $116 million and a negative P/E, but it recent", "url": "https://www.marketbeat.com/instant-alerts/fortress-biotech-nasdaqfbio-shares-cross-above-200-day-moving-average-whats-next-2026-02-11/", "source_name": "MarketBeat", "published_at": "2026-02-11T07:58:20", "published_display": "11 Feb 2026 07:58", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fortress Biotech Achieves Landmark FDA Approval for Rare Pediatric Disease Treatment ()", "summary": "Fortress Biotech and its subsidiary Cyprium Therapeutics received FDA approval for ZYCUBO, the first and only approved treatment for Menkes disease in pediatric patients. This approval, based on compelling clinical data showing significant survival benefits, triggers a Rare Pedia", "url": "https://www.aktiencheck.de/news/Artikel-Fortress_Biotech_Achieves_Landmark_FDA_Approval_for_Rare_Pediatric_Disease_Treatment-19454865", "source_name": "Aktiencheck", "published_at": "2026-02-10T00:59:09", "published_display": "10 Feb 2026 00:59", "sentiment": "positive", "sentiment_pct": 92, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fortress Biotech, Inc. (NASDAQ:FBIO) Might Not Be As Mispriced As It Looks After Plunging 28%", "summary": "Fortress Biotech (NASDAQ:FBIO) shares have dropped 28% in the last month, though they are still up 65% over the past year. Despite a low price-to-sales (P/S) ratio of 1.5x compared to an industry average of 11.5x, its declining revenue and market skepticism about future growth fo", "url": "https://news.futunn.com/en/post/68486508/fortress-biotech-inc-nasdaq-fbio-might-not-be-as-mispriced", "source_name": "\u5bcc\u9014\u725b\u725b", "published_at": "2026-02-06T03:28:47", "published_display": "06 Feb 2026 03:28", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Market Cool On Fortress Biotech, Inc.'s (NASDAQ:FBIO) Revenues Pushing Shares 28% Lower", "summary": "Fortress Biotech's shares have fallen 28% in the last month, though they are still up 65% over the year. The company's price-to-sales (P/S) ratio of 1.5x is considerably lower than the industry average, largely due to a 24% decline in revenue last year. Despite analyst forecasts ", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-fbio/fortress-biotech/news/market-cool-on-fortress-biotech-incs-nasdaqfbio-revenues-pus", "source_name": "Simply Wall Street", "published_at": "2026-02-06T02:29:08", "published_display": "06 Feb 2026 02:29", "sentiment": "negative", "sentiment_pct": 35, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "(FBIOP) Movement Within Algorithmic Entry Frameworks", "summary": "This article analyzes Fortress Biotech Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock (FBIOP) using AI models, identifying weak near-term sentiment but strong mid and long-term support signals. It provides three distinct AI-generated trading strategies: a Po", "url": "https://news.stocktradersdaily.com/news_release/16/FBIOP_Movement_Within_Algorithmic_Entry_Frameworks_020226012001_1770056401.html", "source_name": "Stock Traders Daily", "published_at": "2026-02-02T18:20:00", "published_display": "02 Feb 2026 18:20", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fortress Biotech Leads High-Performing Stocks with 93.1% Return", "summary": "Fortress Biotech, Inc. has demonstrated strong performance over the past year, leading with a 93.1% return in the Pharmaceuticals & Biotechnology sector. Other high-performing stocks include GigaCloud Technology, Inc. with a 91.39% return in Trading & Distributors, and The Toro C", "url": "https://www.marketsmojo.com/news/stock-market-news/fortress-biotech-leads-high-performing-stocks-with-931-return-3811762", "source_name": "Markets Mojo", "published_at": "2026-01-30T15:31:11", "published_display": "30 Jan 2026 15:31", "sentiment": "positive", "sentiment_pct": 90, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How (FBIOP) Movements Inform Risk Allocation Models", "summary": "This article analyzes Fortress Biotech Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock (FBIOP) using AI models to provide trading strategies. It highlights a near-term neutral sentiment but mid and long-term strength, along with identifying support and resist", "url": "https://news.stocktradersdaily.com/news_release/150/How_FBIOP_Movements_Inform_Risk_Allocation_Models_012226121202_1769101922.html", "source_name": "Stock Traders Daily", "published_at": "2026-01-22T12:12:00", "published_display": "22 Jan 2026 12:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fortress Biotech, Inc. (NASDAQ:FBIO) Could Be Less Than A Year Away From Profitability", "summary": "Fortress Biotech, Inc. (NASDAQ:FBIO), a biopharmaceutical company, is projected by analysts to achieve profitability within 12 months, moving from a significant loss in previous years to an anticipated profit of US$1.3 million in 2026. This turnaround requires an aggressive avera", "url": "https://sg.finance.yahoo.com/news/fortress-biotech-inc-nasdaq-fbio-125146346.html", "source_name": "Market source", "published_at": "2026-01-18T12:27:55", "published_display": "18 Jan 2026 12:27", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zacks Research Upgrades Fortress Biotech (NASDAQ:FBIO) to Strong-Buy", "summary": "Zacks Research has upgraded Fortress Biotech (NASDAQ:FBIO) from \"hold\" to \"Strong-Buy,\" while MarketBeat maintains a \"Moderate Buy\" consensus with a target price of $16.50. Shares increased by 6.1%, opening at $3.48, and the biopharmaceutical company recently beat EPS estimates (", "url": "https://www.marketbeat.com/instant-alerts/zacks-research-upgrades-fortress-biotech-nasdaqfbio-to-strong-buy-2026-01-16/", "source_name": "MarketBeat", "published_at": "2026-01-16T13:27:36", "published_display": "16 Jan 2026 13:27", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Approval of ZYCUBO, the First and Only Approved Treatment for Menkes Disease in the United States", "summary": "Fortress Biotech and its subsidiary Cyprium Therapeutics announced that the U.S. FDA has approved ZYCUBO (copper histidinate) for treating Menkes disease in pediatric patients, marking the first and only approved treatment for this rare and often fatal condition. The approval inc", "url": "https://www.marketscreener.com/news/fortress-biotech-and-cyprium-therapeutics-announce-u-s-fda-approval-of-zycubo-the-first-and-only-a-ce7e58d8de81f125", "source_name": "www.marketscreener.com", "published_at": "2026-01-14T12:27:57", "published_display": "14 Jan 2026 12:27", "sentiment": "positive", "sentiment_pct": 91, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "US FDA approves Fortress Bio and Zydus\u2019 treatment for a rare pediatric disease", "summary": "The U.S. FDA has approved Zycubo, a drug developed by Fortress Biotech and Zydus Lifesciences, for the treatment of Menkes disease. This marks the first approved treatment for the rare pediatric genetic disorder in the United States, which affects copper absorption and can be fat", "url": "https://whtc.com/2026/01/13/us-fda-approves-fortress-bio-and-zydus-treatment-for-a-rare-pediatric-disease/", "source_name": "WHTC", "published_at": "2026-01-14T11:59:07", "published_display": "14 Jan 2026 11:59", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Approval of ZYCUBO\u00ae (copper histidinate), the First and Only Approved Treatment for Menkes Disease in the United States", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxOQnJsZl9kUkxTS0xsTkM0enhka21kZ0E4R3ZiOUFUTkFZYlp6QXVXRjh2TzlUamFaLVNJZ0M3dHo4eko2Zm5mSHBzdS14cFpONG1SMFl2SUE0NW5pSzNKWkx2dDRWSzI2T192RWtlNENhQ2dFbTJGdWFsRjViWlJETUdBRXlLeVBZdm9ZU054UFNCWVJYcWdr?oc=5", "source_name": "Market source", "published_at": "2026-01-13T08:00:00+00:00", "published_display": "13 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "US FDA approves Fortress Bio and Zydus' treatment for a rare pediatric disease", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1gFBVV95cUxPdmdxWS1xYk56MkRZcjNha1llS3Zfd0Rvb3FiTmQySjltNy1kWXNSeXhYUFZETnprX2kzSDJkV3JNTEZBdndaVkt1NzJfTTltMVY3MHczNUF1MHU1cndvWkZYdEl3UERpZzJ6amZIandiR0RTZWZRWjVKV3d0NF9zcWR4NGh5N3dIZHhtM3BJNFo4cXFuQnZ5Wk9sRngzc3cwOUw1RTVwLWR1VFplbTBFZ09XYlg2UTZLTVljOHFQR1RTSFBJZGVsNjRxejUwakJibEZzWjBn?oc=5", "source_name": "Reuters", "published_at": "2026-01-13T08:00:00+00:00", "published_display": "13 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "With EPS Growth And More, Puma Biotechnology (NASDAQ:PBYI) Makes An Interesting Case", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-12-09T08:00:00+00:00", "published_display": "09 Dec 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Fortress Biotech stock plummets after FDA rejects Menkes disease drug", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxNeHhxN2hJaTdhX2FZbHYyTjY0OWRWU1g2c3BKZ2JpRzdzcGFoU1laR01ZeURDMmlaMjRldTJwLWJCTzMybDFPSFR2UjhZVDVuZGJUTGxmeUtlN3JHcW9nZXo5NEJyY3pScUdCQXRIbS1XMGo4TkhKS3Z4QVE3RFdfX1JZQjBXbWZmcHJabkxMOE9GZFR4dVVKbmtHRkVRZ1JxUm5HV3g1NWxCbHZWMmg4M2hoVUxoNk94RDFvaXpITFJKNzh6RGw4dF9Jcw?oc=5", "source_name": "Investing.com", "published_at": "2025-10-01T07:00:00+00:00", "published_display": "01 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FORTRESS BIOTECH INC 9.375% CUM RED PER PREF SER A USD25.00 Company Profile & Introduction", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAJBVV95cUxPS25OdXVCT3F0cF9VMkQ3bi14SE9lZkpPOVhHZ2hKVmFUbkxMcHlxNVJIUnBNXzc1TzY2R0JaWlFPNWd2bVZuOGkxTFdicDMwLWdEOFdsOVpCNmR1VHNLbFpyaHhZYkY1Q3p4c3lRRDEyUGlZTzhLUXJ3ZWJXV1AtdDhjLUlhME9BSV9zWWtnOFMySVhaQURDMGxiVzdfRFF6d2hMN3MydXVkbk5Yd0J0ZE9ZMzRvMFRubnhfd0xSZGhLRWRGcTdDeEVZZlRjM2pUcHJMb1pPQ095Vmp0RV9XTENFZXlJcVBGMTNXVjg0SVpwYTRkLWhNZXVadDFpV1FWRDJ2Ri0yeEhmcnRMamtBTFpFNENvX0YwWGszQjcxVmxTS1Bi?oc=5", "source_name": "Moomoo", "published_at": "2024-09-04T07:00:00+00:00", "published_display": "04 Sep 2024 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Fortress Biotech Stock - Saturday deep dive on the business model", "summary": "This article provides a deep dive into Fortress Biotech's business model, highlighting its \"hub-and-spoke\" structure through majority or minority-owned subsidiaries. The company acquires and develops biopharmaceutical product candidates in various therapeutic areas like oncology,", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/fortress-biotech-stock-saturday-deep-dive-on-the-business-model/69592719", "source_name": "AD HOC NEWS", "published_at": "2026-06-20T18:43:29", "published_display": "20 Jun 2026 18:43", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fortress Biotech Inc (FBIO) Risk Assessment: Volatility, Financial Risk & Investment Risk", "summary": "", "url": "https://news.google.com/rss/articles/CBMid0FVX3lxTE1wVzV5Rk9sOGNYenZ4Mmk1OVJwMXZaUFBXYUhMNGptWmZqMW1LVmR3cXZOR25yeDV2ZnJwVm0xMFVKRC10bnIyeDl4WTctZGs1SlI1QTh3Rm9jY2VKZXItaWlKa3Vzd25ubkdLSTJGc1dxVnluR01B?oc=5", "source_name": "TradingKey", "published_at": "2026-06-18T10:50:00+00:00", "published_display": "18 Jun 2026 10:50", "sentiment": "negative", "sentiment_pct": 5, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fortress Biotech Inc (FBIO) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Fortress Biotech Inc (FBIO), highlighting its current price momentum score of 8.51 and its position between resistance and support levels. It details various technical indicators like MACD, RSI, and moving averages, offering buy/sell ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-fbio/technical", "source_name": "TradingKey", "published_at": "2026-06-18T11:10:40", "published_display": "18 Jun 2026 11:10", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fortress Biotech Inc (FBIO) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a valuation analysis of Fortress Biotech Inc (FBIO) by TradingKey. It details the company's current valuation score of 9.14, ranking it 48th out of 157 in the Pharmaceuticals industry, and highlights its P/E ratio of 0.80. The article also notes that relevan", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-fbio/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-18T11:10:40", "published_display": "18 Jun 2026 11:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fortress Biotech Inc stock (US32015L1035): Nasdaq-listed biotech moves in low-volume trade ahead of", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxPU0Y4b3M4OEpEOE1VZUJMazVCM0NVT1hTTm41UWRFZFQ3b2E2TFBQMjRHS01SX2R3SUlTZTh5SW9WeHJDd0pHMFlvc1JSc09zbFdaaHBNWmlaTjMzY1F2V0xBVlVaYVQ5eHp1ZVg1YWRTeUVMMnFWd3c4aVhkcEhFU3hhZFp1QUJSRkc3N3ltdXRpSndNNEt0T0NSemFCb1B5TGt3cnd5WlZmeWoxU3M2VGxibzdKcVJMU2ZyUHFxS3VFSEZEZWJFRQ?oc=5", "source_name": "AD HOC NEWS", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fortress Biotech: Is It Time To Pay The Deferred Preferred Stock Dividends? (FBIO)", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxNelREUjIyQ2pLUExaUmZWMVVTNXliRzBxbHpBODdfZWFsbm9USF9FenlxMGpOazhkT094dTRMd1Z5NXZjejlKT0E5bklHQkhsWHNxTzY5bzVZSzN0Mk5uY0Y4emJLajcwY1RyY3phdmhxVFhxVXdOdDFfSFpZWmVTd3lwdnV3c1B3eVlETVNkakJCNEhiVlV5M3c2MGJiOWNzVzdEN1NMcTV0a24wVl80?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-05-29T07:00:00+00:00", "published_display": "29 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fortress Biotech to Participate in A.G.P.\u2019s Annual Virtual Healthcare Conference", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/fortress-biotech-participate-g-p-123000153.html", "source_name": "GlobeNewswire", "published_at": "2026-05-18T12:30:00+00:00", "published_display": "18 May 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fortress Biotech: Q1 Earnings Snapshot", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/fortress-biotech-q1-earnings-snapshot-205038341.html", "source_name": "Associated Press", "published_at": "2026-05-14T20:50:38+00:00", "published_display": "14 May 2026 20:50", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fortress Biotech stock (US32015L1035): Q1 earnings miss on revenue, but EMROSI shows momentum", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxOUDJvVzJSMkNKaWUzY0RLRTBZSzNfeTVjTnVjRndjVWJwaXY5OW9TTDkwWGJIUXpINGJjUmVTQjNudUNrNFlsLWZFWnU0RUl3Vi0tQmxtWWdxU1BCSldVbDNuSWYwYnpYMmw3QkIzYVhzR0I2c3JfYld5NlNhSENjSnF5RF9xakhXZ2xUbGxUUC04dDlTVkdaa0htRy1ESS12eEtTd1E5UnByV0s1YjFZbHhhclFDOHJybHcxN09EMDllanIw?oc=5", "source_name": "AD HOC NEWS", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fortress Biotech Reports First Quarter 2026 Financial Results and Recent Corporate Highlights", "summary": "Fortress Biotech (FBIO) reported strong first-quarter 2026 financial results, with consolidated net income attributable to common stockholders reaching $108.4 million or $3.44 per share (basic). Key drivers included the FDA approval of ZYCUBO\u00ae for Menkes disease and the subsequen", "url": "https://www.globenewswire.com/news-release/2026/05/14/3295389/0/en/fortress-biotech-reports-first-quarter-2026-financial-results-and-recent-corporate-highlights.html", "source_name": "GlobeNewswire", "published_at": "2026-05-13T12:09:19", "published_display": "13 May 2026 12:09", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fortress Biotech to Participate in the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/fortress-biotech-participate-h-c-123000795.html", "source_name": "GlobeNewswire", "published_at": "2026-05-04T12:30:00+00:00", "published_display": "04 May 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fortress Biotech to Receive $205M as Cyprium Agrees Sale of Rare Pediatric Disease Priority Review Voucher", "summary": "Fortress Biotech (FBIO) has announced that Cyprium Therapeutics, a company in which Fortress owns a substantial equity stake, has entered into an agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for $205 million. This sale is expected to generate signifi", "url": "https://www.msn.com/zh-hk/health/other/fortress-biotech-to-receive-205m-as-cyprium-agrees-sale-of-rare-pediatric-disease-priority-review-voucher/ar-AA1WUaUu?apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1&bundles=feat-es2020-t", "source_name": "MSN", "published_at": "2026-04-28T23:39:35", "published_display": "28 Apr 2026 23:39", "sentiment": "positive", "sentiment_pct": 86, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fortress Biotech Reports 2025 Financial Results and Recent Corporate Highlights", "summary": "Fortress Biotech (Nasdaq: FBIO) announced its financial results for the full-year ended December 31, 2025, detailing significant corporate achievements including asset monetizations, regulatory approvals, and advancements in clinical programs. Key highlights include the FDA appro", "url": "https://www.globenewswire.com/news-release/2026/03/31/3266013/28889/en/fortress-biotech-reports-2025-financial-results-and-recent-corporate-highlights.html", "source_name": "GlobeNewswire", "published_at": "2026-04-08T12:39:53", "published_display": "08 Apr 2026 12:39", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fortress Biotech (FBIO) CFO adds 2,967 ESPP shares in exempt grant", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxNM3pUNjNlcGtvYzFBMng4LWJjc0Fpb3NWR1BGY3l0VXhtWVBnNHBvamNuSUJ2QmFqOTBGOExEa084VDVRUWdZeXRZVTQxazJzRzlaNFVtY2ZKY0JPZ3NmMUd5TXNSQTlTNEZKM01UZlg0TVZPblFCZXpyUzljOWQ1NU5ReExVMDRuY09wQWREQkNLYlN5S1k4WUd1dUE2MmF4Z3JESk5uOXdJZTEwLTZ2N2JNaG4?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-01T07:00:00+00:00", "published_display": "01 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fortress Biotech: Q4 Earnings Snapshot", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/fortress-biotech-q4-earnings-snapshot-214658970.html", "source_name": "Associated Press", "published_at": "2026-03-31T21:46:58+00:00", "published_display": "31 Mar 2026 21:46", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rare-disease voucher sale brings Fortress more than $100M", "summary": "Fortress Biotech's subsidiary, Cyprium Therapeutics, has completed the sale of its Rare Pediatric Disease Priority Review Voucher for $205 million. Fortress Biotech anticipates receiving over $100 million from this transaction, which will enhance its financial flexibility for bus", "url": "https://www.stocktitan.net/news/FBIO/fortress-biotech-s-subsidiary-cyprium-therapeutics-closes-sale-of-wlq4ml23znh3.html", "source_name": "Stock Titan", "published_at": "2026-03-30T20:10:15", "published_display": "30 Mar 2026 20:10", "sentiment": "positive", "sentiment_pct": 89, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fortress Biotech\u2019s Subsidiary Cyprium Therapeutics Closes Sale of Rare Pediatric Disease Priority Review Voucher for $205 Million", "summary": "Fortress Biotech's subsidiary, Cyprium Therapeutics, has completed the sale of its Rare Pediatric Disease Priority Review Voucher (PRV) for $205 million. Fortress expects to receive over $100 million from the transaction, enhancing its financial flexibility. The PRV was issued fo", "url": "https://www.manilatimes.net/2026/03/31/tmt-newswire/globenewswire/fortress-biotechs-subsidiary-cyprium-therapeutics-closes-sale-of-rare-pediatric-disease-priority-review-voucher-for-205-million/2310900", "source_name": "The Manila Times", "published_at": "2026-03-30T20:10:15", "published_display": "30 Mar 2026 20:10", "sentiment": "positive", "sentiment_pct": 74, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fortress Biotech\u2019s Subsidiary Cyprium Therapeutics Closes", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwJBVV95cUxOS2lSSVZtcWFYMlo0YkZleDV4eWNVOHlJWGdlZlJTeDVyZUZ0ZlpTYXN3Yi00UVZDMjlkaHJIMFVjbXAxMVdCMWd6S3N3YktqTnl3ekhCeGdfNkZnbVRDOGxEUENuZHJZWDBCYWFWUVEySmQtZHhUcWdGaF85dmdJeHhlWTY1ZHhEaEQzd2gwQVplTFhzVENuam0yU2pYVkRFNEQ2VWlNaGd5eHhnWG9UZzhCQy1mV1NITG5yN0RGajJwLWozWGdaSmFZbzR4R09CMTVPVXAyRjFqbVo3WG5MVF9ybFFaaVc2a0M2UDQzTllwQU9SdXl4c3NkeUVLb3dMc281R0ZtZ09PSkRUNkdJN21qRFVWME91T1Bjb3JNWlV2TTQ2SjNn?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-03-30T07:00:00+00:00", "published_display": "30 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "This Small-Cap Biotech Stock Is Soaring 29% on Excitement Over Its Prostate Cancer Drug", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxPSG1pQzVIRmhqTkhiWXozT29mTWM0UERfakxmOTZzdm5TZ24wZTVqLUpSWlFyWGVmYnlicGE3ZVYxOVotWU5naGM5aUZVakItUGJLTk1ZVE1mclRHd1N3N0FIWkV2TzFrT2lMNFRjcHhnVVBzTk5vNUFkLTgwNExtRWJYN1hVZzRkVjRlTktkNk1jcnpfQklCamN3NA?oc=5", "source_name": "Barron's", "published_at": "2026-02-24T08:00:00+00:00", "published_display": "24 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FBIO Shares Rally After Unit Sells Priority Review Voucher For $205 Million: Retail Now Pins Hopes On Gene Therapy", "summary": "Fortress Biotech's shares rallied by 10% after its majority-owned unit, Cyprium Therapeutics, sold a Rare Pediatric Disease Priority Review Voucher for $205 million to Sentynl Therapeutics. The voucher was issued following the FDA approval of ZYCUBO for Menkes disease, and 20% of", "url": "https://stocktwits.com/news-articles/markets/equity/fbio-shares-rally-after-unit-sells-priority-review-voucher/cZRtxGmR4yo/amp", "source_name": "Stocktwits", "published_at": "2026-02-23T17:08:57", "published_display": "23 Feb 2026 17:08", "sentiment": "positive", "sentiment_pct": 74, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fortress Biotech Inc. Shares Soar After Promising New Developments", "summary": "Fortress Biotech Inc. (FBIO) shares have risen by 9.97% due to positive market reactions to regulatory approvals, strategic partnerships, and strong revenue growth. The company reported $57.7M in revenue and an impressive 71.6% gross margin, with analysts remaining bullish on its", "url": "https://www.timothysykes.com/news/fortress-biotech-inc-fbio-news-2026_02_23-2/", "source_name": "Timothy Sykes", "published_at": "2026-02-23T16:45:48", "published_display": "23 Feb 2026 16:45", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UPDATE: Fortress Biotech\u2019s Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million", "summary": "Fortress Biotech's majority-owned subsidiary, Cyprium Therapeutics, has announced an agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for $205 million. This PRV was issued following the FDA approval of ZYCUBO for Menkes disease, with Sentynl Therapeutics", "url": "https://www.globenewswire.com/news-release/2026/02/23/3242714/28889/en/UPDATE-Fortress-Biotech-s-Subsidiary-Cyprium-Therapeutics-Enters-into-Agreement-to-Sell-Rare-Pediatric-Disease-Priority-Review-Voucher-for-205-Million.html", "source_name": "GlobeNewswire", "published_at": "2026-02-23T14:24:38", "published_display": "23 Feb 2026 14:24", "sentiment": "positive", "sentiment_pct": 72, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fortress Biotech, Inc. and Cyprium Therapeutics Enter Asset Purchase Agreement for $205 Million Rare Pediatric Disease Priority Review Voucher", "summary": "Fortress Biotech, Inc. and its subsidiary Cyprium Therapeutics have agreed to sell a Rare Pediatric Disease Priority Review Voucher for $205 million. This voucher was obtained after the FDA approved ZYCUBO for Menkes disease, with Sentynl Therapeutics handling its commercializati", "url": "https://www.quiverquant.com/news/Fortress+Biotech%2C+Inc.+and+Cyprium+Therapeutics+Enter+Asset+Purchase+Agreement+for+%24205+Million+Rare+Pediatric+Disease+Priority+Review+Voucher", "source_name": "Quiver Quantitative", "published_at": "2026-02-23T14:08:57", "published_display": "23 Feb 2026 14:08", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fortress Biotech's Cyprium To Sell $205 Million Priority Review Voucher; Shares Rise", "summary": "Fortress Biotech's majority-owned subsidiary, Cyprium Therapeutics, has agreed to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for $205 million. This follows the FDA approval of ZUCUBO for Menkes disease. Fortress Biotech (FBIO) shares rose 20% on the news, refle", "url": "https://www.rttnews.com/3624075/fortress-biotech-s-cyprium-to-sell-205-million-priority-review-voucher-shares-rise.aspx", "source_name": "RTTNews", "published_at": "2026-02-23T10:12:00", "published_display": "23 Feb 2026 10:12", "sentiment": "positive", "sentiment_pct": 74, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fortress Biotech (NASDAQ:FBIO) Shares Cross Above 200-Day Moving Average - Here's What Happened", "summary": "Fortress Biotech (NASDAQ:FBIO) shares have surpassed their 200-day moving average, trading as high as $3.54 and closing at $3.45 on Wednesday. The company holds a \"Moderate Buy\" consensus rating from analysts with a target price of $16.50. Wall Street Zen and Zacks recently upgra", "url": "https://www.marketbeat.com/instant-alerts/fortress-biotech-nasdaqfbio-shares-cross-above-200-day-moving-average-heres-what-happened-2026-02-19/", "source_name": "MarketBeat", "published_at": "2026-02-19T09:27:19", "published_display": "19 Feb 2026 09:27", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fortress Biotech: The PRV Catalyst That Could Reprice This Microcap", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxPQi14VVlUSUNmM1JubXFxZ19jVkNBOWpkU01zWEt6Mm4zTnZwSXRhZ3pMVFhFSmhCQUp4ZHZxUjNsUnZ0cUR4UEhRZkI3aERudlFhdTZFcUFxOVJGb044bElybWk1a2VPbnpqRFdGSzBRRHphdlVQYjVmZVNKd2tERUxFcENqZ252YWYtSnhHRXFwcGxkYnVGekZJdW91QUMwUDVQcEVqd2JRNm8?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-02-19T08:00:00+00:00", "published_display": "19 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Behavioral Patterns of FBIOP and Institutional Flows", "summary": "This article analyzes Fortress Biotech Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock (NASDAQ: FBIOP), highlighting weak near and mid-term sentiment but a strong long-term outlook. It presents three AI-generated trading strategies\u2014Position, Momentum Breakout", "url": "https://news.stocktradersdaily.com/news_release/38/Behavioral_Patterns_of_FBIOP_and_Institutional_Flows_021326022802_1771010882.html", "source_name": "Stock Traders Daily", "published_at": "2026-02-13T14:28:00", "published_display": "13 Feb 2026 14:28", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fortress Biotech (NASDAQ:FBIO) Shares Cross Above 200-Day Moving Average - What's Next?", "summary": "Fortress Biotech (NASDAQ:FBIO) shares have risen above their 200-day moving average, reaching $3.74 on high volume, which is considered a bullish technical signal. The company's fundamentals are mixed, with a market capitalization of $116 million and a negative P/E, but it recent", "url": "https://www.marketbeat.com/instant-alerts/fortress-biotech-nasdaqfbio-shares-cross-above-200-day-moving-average-whats-next-2026-02-11/", "source_name": "MarketBeat", "published_at": "2026-02-11T07:58:20", "published_display": "11 Feb 2026 07:58", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fortress Biotech Achieves Landmark FDA Approval for Rare Pediatric Disease Treatment ()", "summary": "Fortress Biotech and its subsidiary Cyprium Therapeutics received FDA approval for ZYCUBO, the first and only approved treatment for Menkes disease in pediatric patients. This approval, based on compelling clinical data showing significant survival benefits, triggers a Rare Pedia", "url": "https://www.aktiencheck.de/news/Artikel-Fortress_Biotech_Achieves_Landmark_FDA_Approval_for_Rare_Pediatric_Disease_Treatment-19454865", "source_name": "Aktiencheck", "published_at": "2026-02-10T00:59:09", "published_display": "10 Feb 2026 00:59", "sentiment": "positive", "sentiment_pct": 92, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fortress Biotech, Inc. (NASDAQ:FBIO) Might Not Be As Mispriced As It Looks After Plunging 28%", "summary": "Fortress Biotech (NASDAQ:FBIO) shares have dropped 28% in the last month, though they are still up 65% over the past year. Despite a low price-to-sales (P/S) ratio of 1.5x compared to an industry average of 11.5x, its declining revenue and market skepticism about future growth fo", "url": "https://news.futunn.com/en/post/68486508/fortress-biotech-inc-nasdaq-fbio-might-not-be-as-mispriced", "source_name": "\u5bcc\u9014\u725b\u725b", "published_at": "2026-02-06T03:28:47", "published_display": "06 Feb 2026 03:28", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Market Cool On Fortress Biotech, Inc.'s (NASDAQ:FBIO) Revenues Pushing Shares 28% Lower", "summary": "Fortress Biotech's shares have fallen 28% in the last month, though they are still up 65% over the year. The company's price-to-sales (P/S) ratio of 1.5x is considerably lower than the industry average, largely due to a 24% decline in revenue last year. Despite analyst forecasts ", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-fbio/fortress-biotech/news/market-cool-on-fortress-biotech-incs-nasdaqfbio-revenues-pus", "source_name": "Simply Wall Street", "published_at": "2026-02-06T02:29:08", "published_display": "06 Feb 2026 02:29", "sentiment": "negative", "sentiment_pct": 35, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "(FBIOP) Movement Within Algorithmic Entry Frameworks", "summary": "This article analyzes Fortress Biotech Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock (FBIOP) using AI models, identifying weak near-term sentiment but strong mid and long-term support signals. It provides three distinct AI-generated trading strategies: a Po", "url": "https://news.stocktradersdaily.com/news_release/16/FBIOP_Movement_Within_Algorithmic_Entry_Frameworks_020226012001_1770056401.html", "source_name": "Stock Traders Daily", "published_at": "2026-02-02T18:20:00", "published_display": "02 Feb 2026 18:20", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fortress Biotech Leads High-Performing Stocks with 93.1% Return", "summary": "Fortress Biotech, Inc. has demonstrated strong performance over the past year, leading with a 93.1% return in the Pharmaceuticals & Biotechnology sector. Other high-performing stocks include GigaCloud Technology, Inc. with a 91.39% return in Trading & Distributors, and The Toro C", "url": "https://www.marketsmojo.com/news/stock-market-news/fortress-biotech-leads-high-performing-stocks-with-931-return-3811762", "source_name": "Markets Mojo", "published_at": "2026-01-30T15:31:11", "published_display": "30 Jan 2026 15:31", "sentiment": "positive", "sentiment_pct": 90, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How (FBIOP) Movements Inform Risk Allocation Models", "summary": "This article analyzes Fortress Biotech Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock (FBIOP) using AI models to provide trading strategies. It highlights a near-term neutral sentiment but mid and long-term strength, along with identifying support and resist", "url": "https://news.stocktradersdaily.com/news_release/150/How_FBIOP_Movements_Inform_Risk_Allocation_Models_012226121202_1769101922.html", "source_name": "Stock Traders Daily", "published_at": "2026-01-22T12:12:00", "published_display": "22 Jan 2026 12:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fortress Biotech, Inc. (NASDAQ:FBIO) Could Be Less Than A Year Away From Profitability", "summary": "Fortress Biotech, Inc. (NASDAQ:FBIO), a biopharmaceutical company, is projected by analysts to achieve profitability within 12 months, moving from a significant loss in previous years to an anticipated profit of US$1.3 million in 2026. This turnaround requires an aggressive avera", "url": "https://sg.finance.yahoo.com/news/fortress-biotech-inc-nasdaq-fbio-125146346.html", "source_name": "Market source", "published_at": "2026-01-18T12:27:55", "published_display": "18 Jan 2026 12:27", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zacks Research Upgrades Fortress Biotech (NASDAQ:FBIO) to Strong-Buy", "summary": "Zacks Research has upgraded Fortress Biotech (NASDAQ:FBIO) from \"hold\" to \"Strong-Buy,\" while MarketBeat maintains a \"Moderate Buy\" consensus with a target price of $16.50. Shares increased by 6.1%, opening at $3.48, and the biopharmaceutical company recently beat EPS estimates (", "url": "https://www.marketbeat.com/instant-alerts/zacks-research-upgrades-fortress-biotech-nasdaqfbio-to-strong-buy-2026-01-16/", "source_name": "MarketBeat", "published_at": "2026-01-16T13:27:36", "published_display": "16 Jan 2026 13:27", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Approval of ZYCUBO, the First and Only Approved Treatment for Menkes Disease in the United States", "summary": "Fortress Biotech and its subsidiary Cyprium Therapeutics announced that the U.S. FDA has approved ZYCUBO (copper histidinate) for treating Menkes disease in pediatric patients, marking the first and only approved treatment for this rare and often fatal condition. The approval inc", "url": "https://www.marketscreener.com/news/fortress-biotech-and-cyprium-therapeutics-announce-u-s-fda-approval-of-zycubo-the-first-and-only-a-ce7e58d8de81f125", "source_name": "www.marketscreener.com", "published_at": "2026-01-14T12:27:57", "published_display": "14 Jan 2026 12:27", "sentiment": "positive", "sentiment_pct": 91, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "US FDA approves Fortress Bio and Zydus\u2019 treatment for a rare pediatric disease", "summary": "The U.S. FDA has approved Zycubo, a drug developed by Fortress Biotech and Zydus Lifesciences, for the treatment of Menkes disease. This marks the first approved treatment for the rare pediatric genetic disorder in the United States, which affects copper absorption and can be fat", "url": "https://whtc.com/2026/01/13/us-fda-approves-fortress-bio-and-zydus-treatment-for-a-rare-pediatric-disease/", "source_name": "WHTC", "published_at": "2026-01-14T11:59:07", "published_display": "14 Jan 2026 11:59", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Approval of ZYCUBO\u00ae (copper histidinate), the First and Only Approved Treatment for Menkes Disease in the United States", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxOQnJsZl9kUkxTS0xsTkM0enhka21kZ0E4R3ZiOUFUTkFZYlp6QXVXRjh2TzlUamFaLVNJZ0M3dHo4eko2Zm5mSHBzdS14cFpONG1SMFl2SUE0NW5pSzNKWkx2dDRWSzI2T192RWtlNENhQ2dFbTJGdWFsRjViWlJETUdBRXlLeVBZdm9ZU054UFNCWVJYcWdr?oc=5", "source_name": "Market source", "published_at": "2026-01-13T08:00:00+00:00", "published_display": "13 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "US FDA approves Fortress Bio and Zydus' treatment for a rare pediatric disease", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1gFBVV95cUxPdmdxWS1xYk56MkRZcjNha1llS3Zfd0Rvb3FiTmQySjltNy1kWXNSeXhYUFZETnprX2kzSDJkV3JNTEZBdndaVkt1NzJfTTltMVY3MHczNUF1MHU1cndvWkZYdEl3UERpZzJ6amZIandiR0RTZWZRWjVKV3d0NF9zcWR4NGh5N3dIZHhtM3BJNFo4cXFuQnZ5Wk9sRngzc3cwOUw1RTVwLWR1VFplbTBFZ09XYlg2UTZLTVljOHFQR1RTSFBJZGVsNjRxejUwakJibEZzWjBn?oc=5", "source_name": "Reuters", "published_at": "2026-01-13T08:00:00+00:00", "published_display": "13 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fortress Biotech stock plummets after FDA rejects Menkes disease drug", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxNeHhxN2hJaTdhX2FZbHYyTjY0OWRWU1g2c3BKZ2JpRzdzcGFoU1laR01ZeURDMmlaMjRldTJwLWJCTzMybDFPSFR2UjhZVDVuZGJUTGxmeUtlN3JHcW9nZXo5NEJyY3pScUdCQXRIbS1XMGo4TkhKS3Z4QVE3RFdfX1JZQjBXbWZmcHJabkxMOE9GZFR4dVVKbmtHRkVRZ1JxUm5HV3g1NWxCbHZWMmg4M2hoVUxoNk94RDFvaXpITFJKNzh6RGw4dF9Jcw?oc=5", "source_name": "Investing.com", "published_at": "2025-10-01T07:00:00+00:00", "published_display": "01 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FORTRESS BIOTECH INC 9.375% CUM RED PER PREF SER A USD25.00 Company Profile & Introduction", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAJBVV95cUxPS25OdXVCT3F0cF9VMkQ3bi14SE9lZkpPOVhHZ2hKVmFUbkxMcHlxNVJIUnBNXzc1TzY2R0JaWlFPNWd2bVZuOGkxTFdicDMwLWdEOFdsOVpCNmR1VHNLbFpyaHhZYkY1Q3p4c3lRRDEyUGlZTzhLUXJ3ZWJXV1AtdDhjLUlhME9BSV9zWWtnOFMySVhaQURDMGxiVzdfRFF6d2hMN3MydXVkbk5Yd0J0ZE9ZMzRvMFRubnhfd0xSZGhLRWRGcTdDeEVZZlRjM2pUcHJMb1pPQ095Vmp0RV9XTENFZXlJcVBGMTNXVjg0SVpwYTRkLWhNZXVadDFpV1FWRDJ2Ri0yeEhmcnRMamtBTFpFNENvX0YwWGszQjcxVmxTS1Bi?oc=5", "source_name": "Moomoo", "published_at": "2024-09-04T07:00:00+00:00", "published_display": "04 Sep 2024 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxNZXlTZHFHZVNxMktqZ0hVNURmdE1hUFpZZnlfdEVhMnVla2EyTWN6b2YwNkVhNllxUy1Bczl2a0ZUNk04Q3oyTEZSajdpMnFDVXJfRTlfLUdHQ05uS3FQZkhNWkJ0MDFENDJvRXR0ZGV1RDlYVmdWem96V29NeTg4YWRZWGNoMzM1emRoSExJbXdwZnJIWHpsYjVnT0FQVHZtUW5iVg?oc=5", "source_name": "Market source", "published_at": "2026-03-30T07:00:00+00:00", "published_display": "30 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "With EPS Growth And More, Puma Biotechnology (NASDAQ:PBYI) Makes An Interesting Case", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-12-09T08:00:00+00:00", "published_display": "09 Dec 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 105, "total_relevant": 49, "sentiment_summary": {"positive": 21, "negative": 4, "neutral": 24, "score": 61, "total": 49, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 77, "events": [{"event": "general", "label": "Market update", "weight": 13.5, "count": 22}, {"event": "earnings", "label": "Earnings", "weight": 9.09, "count": 17}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 3.3, "count": 6}, {"event": "guidance", "label": "Guidance", "weight": 1.1, "count": 2}, {"event": "deals", "label": "Deals and strategy", "weight": 0.55, "count": 1}, {"event": "analyst", "label": "Analyst action", "weight": 0.55, "count": 1}], "positive_events": 21, "negative_events": 4}, "market_context": {"has_market_context": true, "latest_close": 2.99, "latest_week": "2026-06-19", "one_week_move": 7.9, "four_week_move": 9.1, "twelve_week_move": 8.3, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -0.074793, "market_dynamics_buy_signal": false, "relative_strength": -12.637922, "fair_value_gap": 11.3, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "undecided", "expectation_probability": 45.656, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+7.9% over one week, +9.1% over four weeks, trend inactive, and near fair-value range."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "positive", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 70, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 7}, {"label": "GlobeNewswire", "count": 6}, {"label": "AD HOC NEWS", "count": 3}, {"label": "TradingKey", "count": 3}, {"label": "MarketBeat", "count": 3}, {"label": "Stock Traders Daily", "count": 3}, {"label": "Seeking Alpha", "count": 2}, {"label": "simplywall.st", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 42}, {"label": "Industry context", "count": 7}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 22}, {"label": "Earnings", "count": 17}, {"label": "Regulatory and legal", "count": 6}, {"label": "Guidance", "count": 2}, {"label": "Deals and strategy", "count": 1}, {"label": "Analyst action", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "61/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "positive", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "77/100 classification confidence."}, {"label": "Company focus", "value": "42", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "6", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "+7.9% over one week, +9.1% over four weeks, trend inactive, and near fair-value range."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "Fortress Biotech Stock - Saturday deep dive on the business model"}], "updated_at": "2026-06-23T01:35:20.187777+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}